Novartis AG

NOVN

CH0012005267

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).

Sector

Pharmaceuticals

Calendar

2024-01-07 - JPMorgan Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : Healthy Q3; guidance upgraded ‘again’

October 24, 2023 at 10:00 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

98.65USD

Average target price

105.6USD

Spread / Average Target

+7.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+1.76%	203 B $
ELI LILLY AND COMPANY	+61.43%	527 B $
NOVO NORDISK A/S	+46.50%	448 B $
JOHNSON & JOHNSON	-10.37%	382 B $
MERCK & CO., INC.	-4.41%	266 B $
ABBVIE INC.	-10.80%	255 B $
ROCHE HOLDING AG	-13.61%	227 B $
ASTRAZENECA PLC	-9.57%	201 B $
PFIZER, INC.	-43.05%	165 B $
AMGEN INC.	+3.03%	146 B $

Other Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:35 2023-12-05 am EST			5-day change	1st Jan Change
85.06 ^CHF	-1.25%		-0.26%	+1.76%

03:38pm	Anything is possible
02:17pm	Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	MT

Anything is possible	09:38am
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	08:17am	MT
NOVARTIS AG : JP Morgan remains Neutral	03:58am	ZD
Blackstone explores sale of Anthos Therapeutics -sources	06:35pm	RE
Blackstone Mulling Potential Sale of Blood-Thinner Developer Anthos	Dec. 04	MT
Blackstone explores sale of Anthos Therapeutics -sources	Dec. 04	RE
NOVARTIS AG : Deutsche Bank gives a Buy rating	Nov. 30	ZD
NOVARTIS : Oddo BHF confirms its recommendation after R&D day	Nov. 29	CF
NOVARTIS AG : Sell rating from Barclays	Nov. 29	ZD
Novartis' Kymriah, Other CAR-T Cancer Therapies Under US Investigation Over Alleged Safety Issues	Nov. 29	MT
US FDA investigating safety risk of CAR-T cancer therapies	Nov. 28	RE
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup	Nov. 28	DJ
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells	Nov. 28	DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies	Nov. 28	MT
US FDA investigating safety risk of CAR-T therapies	Nov. 28	RE
Swiss Market Index Slumps Ahead of Key Inflation Reports	Nov. 28	MT
Novartis raises sales growth target	Nov. 28	RE
Transcript : Novartis AG - Special Call	Nov. 28	CI
European Midday Briefing : Stocks Struggle Again as November Rally Continues to Stall	Nov. 28	DJ
NOVARTIS AG : Gets a Neutral rating from UBS	Nov. 28	ZD
NOVARTIS : price target maintained by Oddo BHF	Nov. 28	CF
NOVARTIS AG : Jefferies reaffirms its Buy rating	Nov. 28	ZD
Novartis Touts R&D Pipeline Progress, Upgraded Midterm Targets as Pure-play Medicines Company	Nov. 28	MT
Novartis lifts sales growth target to 5% per year through 2027	Nov. 28	RE
Novartis Raises Mid-Term Sales Growth Targets	Nov. 28	DJ